Purchase this article with an account.
RP Kowalski, LM Karenchak, EG Romanowski, FS Mah, DC Ritterband, YJ Gordon; An In Vitro Comparison of 2nd, 3rd, and 4th Generation Fluoroquinolones Against Bacterial Keratitis Isolates . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1585.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Purpose: In the future there will be five topical fluoroquinolones on the market. We compared the in vitro susceptibilities of bacterial keratitis isolates to ciprofloxacin 2nd-gen (C), ofloxacin 2nd-gen (O), levofloxacin 3rd-gen (L), moxifloxacin 4th-gen (M), and gatifloxacin 4th-gen (G). Methods: The MICs (µg/ml) of 177 bacterial keratitis isolates were determined using Etests. The bacterial susceptibilities were determined with the NCCLS standards and were compared statistically along with the potencies (isolates with the lowest MICs). Results: View OriginalDownload SlideView OriginalDownload Slide Qr, Qs- resistant or susceptible to ciprofloxacin and ofloxacin by disk diffusion. Conclusion: The 4th generation moxifloxacin and gatifloxacin demonstrated increased potency for gram positive bacteria over levofloxacin, ciprofloxacin, and ofloxacin, along with better in vitro susceptibility for isolates that were 2nd and 3rd generation fluoroquinolone-resistant. The 4th generations demonstrated no advantage for gram negative coverage. Clinical studies are needed to confirm our in vitro results.
This PDF is available to Subscribers Only